MeSH term
Frequency | Condition_Probility | Animals | 51 | 0.0 |
Humans | 111 | 0.0 |
Cytokines/pharmacology | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 17 | 0.0 |
In Vitro | 5 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
*Milk Proteins | 18 | 3.0 |
Signal Transduction | 25 | 0.0 |
Trans-Activators/*metabolism | 17 | 1.0 |
Amino Acid Sequence | 10 | 0.0 |
Dimerization | 6 | 0.0 |
Interleukin-12/pharmacology | 9 | 18.0 |
Mice | 41 | 0.0 |
Mice, Inbred BALB C | 11 | 0.0 |
Molecular Sequence Data | 16 | 0.0 |
Research Support, Non-U.S. Gov't | 78 | 0.0 |
Signal Transduction/drug effects | 4 | 0.0 |
DNA-Binding Proteins/physiology | 2 | 0.0 |
Trans-Activators/*physiology | 9 | 3.0 |
COS Cells | 3 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
Cells, Cultured | 38 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 40 | 0.0 |
Base Sequence | 19 | 0.0 |
DNA Primers | 3 | 0.0 |
Dendritic Cells/immunology/*metabolism | 2 | 11.0 |
Female | 14 | 0.0 |
Interferon Type II/*physiology | 2 | 3.0 |
Mice, Inbred C57BL | 7 | 0.0 |
Up-Regulation | 7 | 0.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
DNA-Binding Proteins/metabolism | 15 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
NF-kappa B/physiology | 2 | 2.0 |
Phosphorylation | 39 | 0.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Trans-Activators/metabolism | 17 | 1.0 |
Tyrosine/metabolism | 15 | 1.0 |
Flow Cytometry | 11 | 0.0 |
Interleukin-12/*pharmacology | 12 | 24.0 |
Lymphocyte Activation | 9 | 0.0 |
Mice, Knockout | 9 | 0.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Receptors, Interleukin/biosynthesis/genetics | 2 | 28.0 |
DNA-Binding Proteins/immunology | 2 | 9.0 |
Interferon Type II/*biosynthesis | 4 | 2.0 |
Models, Immunological | 2 | 0.0 |
Trans-Activators/immunology | 2 | 14.0 |
Signal Transduction/*physiology | 3 | 0.0 |
Cell Line | 16 | 0.0 |
Drug Synergism | 7 | 0.0 |
Interferon Type II/*biosynthesis/genetics | 4 | 19.0 |
Interferon-alpha/*pharmacology | 3 | 2.0 |
Interleukin-18/*pharmacology | 3 | 25.0 |
Killer Cells, Natural/*immunology | 2 | 0.0 |
Kinetics | 2 | 0.0 |
Phosphotyrosine/metabolism | 2 | 0.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Comparative Study | 11 | 0.0 |
Immunity, Cellular | 2 | 0.0 |
Interferon Type II/biosynthesis | 9 | 1.0 |
Interleukin-12/metabolism/*physiology | 2 | 66.0 |
Lymphocyte Activation/immunology | 3 | 0.0 |
Signal Transduction/*immunology | 11 | 2.0 |
Binding Sites/genetics | 2 | 0.0 |
DNA/genetics/metabolism | 2 | 0.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
Interferon Type I, Recombinant/*pharmacology | 2 | 4.0 |
Adult | 9 | 0.0 |
Aged | 2 | 0.0 |
Male | 8 | 0.0 |
Middle Aged | 4 | 0.0 |
*Proto-Oncogene Proteins | 14 | 0.0 |
*Signal Transduction | 5 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
DNA-Binding Proteins/drug effects/genetics/*metabolism | 2 | 14.0 |
Feedback | 2 | 1.0 |
T-Lymphocytes/metabolism | 3 | 1.0 |
Trans-Activators/drug effects/genetics/*metabolism | 2 | 16.0 |
Cytokines/*genetics/immunology | 2 | 22.0 |
*Gene Expression Regulation | 2 | 0.0 |
Interferon Type II/immunology | 2 | 2.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 2 | 1.0 |
Th1 Cells/immunology | 6 | 3.0 |
Th2 Cells/immunology | 3 | 1.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Mutation | 6 | 0.0 |
Receptors, Interleukin/*genetics | 3 | 9.0 |
DNA-Binding Proteins/genetics/*metabolism | 8 | 0.0 |
Hypersensitivity/immunology | 2 | 5.0 |
Interferon Type II/immunology/metabolism | 2 | 14.0 |
Interleukin-12/immunology/*pharmacology | 2 | 66.0 |
Phenotype | 5 | 0.0 |
Receptors, Interleukin/metabolism | 2 | 3.0 |
Th2 Cells/*drug effects/immunology/*metabolism | 2 | 100.0 |
Trans-Activators/genetics/*metabolism | 7 | 1.0 |
Th1 Cells/cytology/*immunology | 2 | 20.0 |
DNA-Binding Proteins/*immunology | 2 | 8.0 |
Th1 Cells/*immunology | 2 | 1.0 |
Trans-Activators/*immunology | 2 | 16.0 |
Blotting, Western | 4 | 0.0 |
Time Factors | 6 | 0.0 |
Transcription Factors/metabolism | 5 | 0.0 |
Interleukin-12/*metabolism | 4 | 30.0 |
Th1 Cells | 2 | 16.0 |
Interleukin-18/physiology | 2 | 33.0 |
Protein-Tyrosine Kinase/metabolism | 5 | 0.0 |
Proteins/metabolism | 5 | 0.0 |
Signal Transduction/genetics/*immunology | 2 | 2.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Sequence Analysis | 2 | 0.0 |
Child, Preschool | 4 | 0.0 |
Cytotoxicity, Immunologic | 2 | 0.0 |
Enzyme Activation/immunology | 2 | 1.0 |
Infant | 4 | 0.0 |
T-Lymphocytes/immunology/metabolism | 3 | 2.0 |
Amino Acid Substitution | 2 | 0.0 |
Interferon-alpha/pharmacology | 4 | 4.0 |
Ligands | 4 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Phosphorylation/drug effects | 5 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Recombinant Proteins/pharmacology | 4 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Tyrosine/*metabolism | 2 | 0.0 |
3T3 Cells | 2 | 0.0 |
Jurkat Cells | 2 | 0.0 |
Transfection | 4 | 0.0 |
Adolescent | 5 | 0.0 |
Child | 5 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Interleukin-12/*immunology | 3 | 20.0 |
Interleukin-4/metabolism | 3 | 3.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
Trans-Activators/genetics/metabolism | 2 | 1.0 |
Binding Sites | 7 | 0.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
DNA-Binding Proteins/metabolism/*physiology | 3 | 2.0 |
Down-Regulation | 4 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Interferon Type II/*genetics | 2 | 3.0 |
Models, Genetic | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Protein Binding | 4 | 0.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Trans-Activators/metabolism/*physiology | 4 | 6.0 |
Cell Differentiation | 4 | 0.0 |
Cell Division | 3 | 0.0 |
Interleukin-12/metabolism | 3 | 5.0 |
Signal Transduction/*drug effects/*immunology | 2 | 66.0 |
Disease Models, Animal | 2 | 0.0 |
Models, Biological | 4 | 0.0 |
DNA-Binding Proteins/*physiology | 7 | 1.0 |
Interleukin-2/*pharmacology | 3 | 1.0 |
Protein-Tyrosine Kinase/physiology | 2 | 1.0 |
DNA Primers/genetics | 3 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Immunosuppressive Agents/*pharmacology | 3 | 1.0 |
Signal Transduction/drug effects/immunology | 3 | 6.0 |
Trans-Activators/*antagonists & inhibitors/metabolism | 3 | 15.0 |
Interleukin-12/*antagonists & inhibitors/*physiology | 2 | 100.0 |
Interleukin-12/*physiology | 4 | 21.0 |
Receptors, Interleukin/*physiology | 2 | 8.0 |
DNA-Binding Proteins/*antagonists & inhibitors/metabolism | 2 | 6.0 |
Immune Sera/pharmacology | 2 | 2.0 |
DNA/metabolism | 6 | 0.0 |
DNA-Binding Proteins/chemistry/*metabolism | 2 | 1.0 |
Receptors, Interleukin/chemistry/*metabolism | 3 | 33.0 |
Trans-Activators/chemistry/*metabolism | 2 | 3.0 |
src Homology Domains | 2 | 0.0 |
Interferon-alpha/physiology | 2 | 25.0 |
Interleukin-12/antagonists & inhibitors/*physiology | 2 | 66.0 |
Killer Cells, Natural/*metabolism | 2 | 3.0 |
Signal Transduction/genetics/immunology | 2 | 2.0 |
T-Lymphocytes/*metabolism | 3 | 0.0 |
Trans-Activators/physiology | 2 | 1.0 |
Up-Regulation/genetics/immunology | 3 | 5.0 |
Enzyme Activation | 3 | 0.0 |
Interferons/pharmacology | 2 | 2.0 |
Interleukin-12/pharmacology/*physiology | 3 | 60.0 |
Killer Cells, Natural/*immunology/metabolism | 2 | 5.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Interferon Type II/metabolism | 3 | 1.0 |
Interleukin-4/pharmacology | 3 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
*Mitogen-Activated Protein Kinases | 2 | 0.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 6 | 0.0 |
Cytokines/*metabolism | 2 | 0.0 |
Signal Transduction/physiology | 2 | 0.0 |
Interleukin-15/pharmacology | 3 | 13.0 |
Gene Expression Regulation/drug effects/*immunology | 2 | 6.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Interferon Type II/*metabolism | 3 | 4.0 |
Interleukin-2/pharmacology | 6 | 1.0 |
Interleukins/*pharmacology | 2 | 2.0 |
Lymphocyte Activation/*drug effects | 4 | 1.0 |
Cytokines/metabolism | 3 | 0.0 |
Interleukins/*metabolism | 2 | 15.0 |
Killer Cells, Natural/metabolism | 2 | 3.0 |
Retroviridae/genetics | 2 | 0.0 |
Interleukin-2/*physiology | 2 | 2.0 |
Interphase/immunology | 2 | 4.0 |
Protein Binding/immunology | 2 | 1.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Interleukin-4/*physiology | 2 | 4.0 |
Receptors, Interleukin/biosynthesis | 4 | 25.0 |
Clone Cells | 3 | 0.0 |
Interleukin-12/metabolism/*pharmacology | 2 | 50.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Promoter Regions (Genetics)/immunology | 3 | 4.0 |
Receptors, IgG/metabolism | 2 | 2.0 |
Cloning, Molecular | 4 | 0.0 |
Protein Conformation | 2 | 0.0 |
Lymphocyte Activation/genetics | 2 | 2.0 |
Protein-Tyrosine Kinase/*physiology | 2 | 1.0 |
Th1 Cells/*physiology | 2 | 11.0 |
Cell Division/drug effects | 3 | 0.0 |
DNA-Binding Proteins/antagonists & inhibitors/*metabolism | 3 | 11.0 |
Trans-Activators/antagonists & inhibitors/*metabolism | 3 | 13.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Repressor Proteins/metabolism | 3 | 1.0 |
Gene Expression | 3 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Serine/metabolism | 2 | 0.0 |
Receptors, Cytokine/metabolism | 2 | 2.0 |
Trans-Activators/*genetics/metabolism | 2 | 1.0 |
Cell Division/immunology | 2 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Signal Transduction/*genetics/*immunology | 2 | 22.0 |
*Repressor Proteins | 2 | 0.0 |
*Transcription Factors | 2 | 0.0 |
Protein Binding/genetics/immunology | 3 | 3.0 |
Cell Differentiation/immunology | 2 | 0.0 |
Antigens, CD2/*physiology | 2 | 8.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Tyrphostins/pharmacology | 2 | 1.0 |
Thyroxine/*blood | 2 | 5.0 |
